Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Trends in Colon and Rectal Cancer Incidence in Australia from 1982 to 2014: Analysis of Data on Over 375,000 Cases.

Feletto E, Yu XQ, Lew JB, St John DJB, Jenkins MA, Macrae FA, Mahady SE, Canfell K.

Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):83-90. doi: 10.1158/1055-9965.EPI-18-0523. Epub 2018 Dec 7.

PMID:
30530848
2.

Revised Australian national guidelines for colorectal cancer screening: family history.

Jenkins MA, Ait Ouakrim D, Boussioutas A, Hopper JL, Ee HC, Emery JD, Macrae FA, Chetcuti A, Wuellner L, St John DJB.

Med J Aust. 2018 Nov 19;209(10):455-460. Epub 2018 Oct 29.

PMID:
30359558
3.

Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.

Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Greuter MJE, Coupé VMH, Canfell K.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1450-1461. doi: 10.1158/1055-9965.EPI-18-0128. Epub 2018 Sep 6.

PMID:
30190276
4.

Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.

Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Sarfati D, Greuter MJE, Coupé VMH, Canfell K.

Int J Cancer. 2018 Jul 15;143(2):269-282. doi: 10.1002/ijc.31314. Epub 2018 Mar 8.

PMID:
29441568
5.

Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.

Lew JB, St John DJB, Xu XM, Greuter MJE, Caruana M, Cenin DR, He E, Saville M, Grogan P, Coupé VMH, Canfell K.

Lancet Public Health. 2017 Jul;2(7):e331-e340. doi: 10.1016/S2468-2667(17)30105-6. Epub 2017 Jun 26.

6.

Re: Double pylorus from a chronic gastric ulcer: an interesting and rare case.

St John DJ.

ANZ J Surg. 2016 May;86(5):422. doi: 10.1111/ans.13445. No abstract available.

PMID:
27109304
7.

Optimising the expansion of the National Bowel Cancer Screening Program.

Cenin DR, St John DJ, Ledger MJ, Slevin T, Lansdorp-Vogelaar I.

Med J Aust. 2014 Oct 20;201(8):456-61.

8.

A comparative case study of bowel cancer screening in the UK and Australia: evidence lost in translation?

Flitcroft KL, St John DJ, Howard K, Carter SM, Pignone MP, Salkeld GP, Trevena LJ.

J Med Screen. 2011;18(4):193-203. doi: 10.1258/jms.2011.011066. Epub 2011 Nov 21. Review.

9.

Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.

Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, St John DJ.

Med J Aust. 2011 Feb 21;194(4):180-5.

10.

Dependence of colorectal cancer risk on the parent-of-origin of mutations in DNA mismatch repair genes.

van Vliet CM, Dowty JG, van Vliet JL, Smith L, Mead LJ, Macrae FA, St John DJ, Giles GG, Southey MC, Jenkins MA, Velan GM, Hopper JL.

Hum Mutat. 2011 Feb;32(2):207-12. doi: 10.1002/humu.21408. Epub 2011 Jan 25.

11.

Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?

Keogh LA, van Vliet CM, Studdert DM, Maskiell JA, Macrae FA, St John DJ, Gaff CL, Young MA, Southey MC, Giles GG, Rosenthal DA, Hopper JL, Jenkins MA.

Med J Aust. 2009 Sep 7;191(5):255-8.

PMID:
19740045
12.

Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review.

Burch JA, Soares-Weiser K, St John DJ, Duffy S, Smith S, Kleijnen J, Westwood M.

J Med Screen. 2007;14(3):132-7. Review.

PMID:
17925085
13.

The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing.

Collins VR, Meiser B, Ukoumunne OC, Gaff C, St John DJ, Halliday JL.

Genet Med. 2007 May;9(5):290-7.

PMID:
17505206
14.

Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes.

Mead LJ, Jenkins MA, Young J, Royce SG, Smith L, St John DJ, Macrae F, Giles GG, Hopper JL, Southey MC.

Clin Cancer Res. 2007 May 15;13(10):2865-9.

15.

Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study.

Jenkins MA, Baglietto L, Dowty JG, Van Vliet CM, Smith L, Mead LJ, Macrae FA, St John DJ, Jass JR, Giles GG, Hopper JL, Southey MC.

Clin Gastroenterol Hepatol. 2006 Apr;4(4):489-98.

PMID:
16616355
16.

Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.

Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, Smith LD, Jennings K, Grubb G, Royce SG, Walsh MD, Barker MA, Young JP, Jass JR, St John DJ, Macrae FA, Giles GG, Hopper JL.

J Clin Oncol. 2005 Sep 20;23(27):6524-32. Epub 2005 Aug 22.

PMID:
16116158
17.
18.

Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer.

Meiser B, Collins V, Warren R, Gaff C, St John DJ, Young MA, Harrop K, Brown J, Halliday J.

Clin Genet. 2004 Dec;66(6):502-11.

PMID:
15521977
19.

Profuse familial adenomatous polyposis with an adenomatous polyposis coli exon 3 mutation.

Nasioulas S, Jones IT, St John DJ, Scott RJ, Forrest SM, McKinlay Gardner RJ.

Fam Cancer. 2001;1(1):3-7.

PMID:
14574009
20.

Prescreening evaluation of a brush-based faecal immunochemical test for haemoglobin.

Young GP, St John DJ, Cole SR, Bielecki BE, Pizzey C, Sinatra MA, Polglase AL, Cadd B, Morcom J.

J Med Screen. 2003;10(3):123-8.

PMID:
14561263
21.

Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.

Young GP, St John DJ, Winawer SJ, Rozen P; WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy).

Am J Gastroenterol. 2002 Oct;97(10):2499-507.

PMID:
12385430
22.

After hMSH2 and hMLH1--what next? Analysis of three-generational, population-based, early-onset colorectal cancer families.

Jenkins MA, Baglietto L, Dite GS, Jolley DJ, Southey MC, Whitty J, Mead LJ, St John DJ, Macrae FA, Bishop DT, Venter DJ, Giles GG, Hopper JL.

Int J Cancer. 2002 Nov 10;102(2):166-71.

23.

Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance.

Brown GJ, St John DJ, Macrae FA, Aittomäki K.

Gynecol Oncol. 2001 Mar;80(3):346-9.

PMID:
11263929
24.

Yield from colonoscopic screening in people with a strong family history of common colorectal cancer.

Dowling DJ, St John DJ, Macrae FA, Hopper JL.

J Gastroenterol Hepatol. 2000 Aug;15(8):939-44.

PMID:
11022837
25.

Faecal occult blood test screening for colorectal cancer--what are we waiting for?

Stanley AJ, St John DJ.

Aust N Z J Med. 1999 Aug;29(4):545-51. No abstract available.

PMID:
10868533
26.

Screening for rectal cancer.

St John DJ.

Hepatogastroenterology. 2000 Mar-Apr;47(32):305-9. Review.

PMID:
10791177
27.

Colorectal cancer screening in general practice. A survey of current practice and attitudes in Victoria.

Martyres R, St John DJ, Irving FH, Wyman K.

Aust Fam Physician. 1999 Jul;28(7):755-8.

PMID:
10431443
28.

E-cadherin unlikely to be a common "low penetrance" gene for colorectal cancer.

Gardner RJ, Gaff CL, Macrae FA, St John DJ, Hopkins J, Guilford PJ, Reeve AE.

Am J Med Genet. 1999 May 21;84(2):169-71. No abstract available.

PMID:
10323744
29.

Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable.

Sinatra MA, St John DJ, Young GP.

Clin Chem. 1999 Jan;45(1):123-6.

30.

Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC.

Rodriguez-Bigas MA, Vasen HF, Lynch HT, Watson P, Myrhøj T, Järvinen HJ, Mecklin JP, Macrae F, St John DJ, Bertario L, Fidalgo P, Madlensky L, Rozen P.

Cancer. 1998 Jul 15;83(2):240-4.

PMID:
9669805
31.

A study of laboratory based faecal occult blood testing in Melbourne, Australia. The Faecal Occult Blood Testing Study Group.

Sinatra MA, Young GP, St John DJ, Blake D, Ratnaike S.

J Gastroenterol Hepatol. 1998 Apr;13(4):396-400.

PMID:
9641304
32.

Colorectal cancer screening: clinical guidelines and rationale.

St John DJ, Macrae FA, Young GP.

Gastroenterology. 1997 Oct;113(4):1422; author reply 1424. No abstract available.

PMID:
9322542
33.

RNA-based mutation screening in hereditary nonpolyposis colorectal cancer.

Kohonen-Corish M, Ross VL, Doe WF, Kool DA, Edkins E, Faragher I, Wijnen J, Khan PM, Macrae F, St John DJ.

Am J Hum Genet. 1996 Oct;59(4):818-24.

34.

Influence of delay in stool sampling on fecal occult blood test sensitivity.

Young GP, Sinatra MA, St John DJ.

Clin Chem. 1996 Jul;42(7):1107-8. No abstract available.

35.

[Prevention of colorectal carcinoma. Current WHO guidelines for early detection of colorectal carcinoma. World Health Organization Collaborating Center for the Prevention of Colorectal Cancer].

Winawer SJ, St John DJ, Bond JH, Rozen P, Burt RW, Waye JD, Kronborg O, O'Brien MJ, Bishop DT, Kurtz RC, Shike M, Swaroop SV, Levin B, Frühmorgen P, Lynch HT.

Leber Magen Darm. 1996 May;26(3):139-40, 143. German. No abstract available.

PMID:
8709827
36.

Guidelines for the prevention of colorectal cancer: update based on new data. World Health Organization Collaborating Center for the Prevention of Colorectal Cancer.

Winawer SJ, St John DJ, Bond JH, Rozen P, Burt RW, Waye JD, Kronborg O, O'Brien MJ, Bishop DT, Kurtz RC, et al.

Z Gastroenterol. 1995 Sep;33(9):574-6. No abstract available.

PMID:
8525666
37.

Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer.

Winawer SJ, St John DJ, Bond JH, Rozen P, Burt RW, Waye JD, Kronborg O, O'Brien MJ, Bishop DT, Kurtz RC, et al.

Bull World Health Organ. 1995;73(1):7-10.

38.

Chromosome 2p linkage analysis in hereditary non-polyposis colon cancer.

Kohonen-Corish MR, Doe WF, St John DJ, Macrae FA.

J Gastroenterol Hepatol. 1995 Jan-Feb;10(1):76-80.

PMID:
7620112
39.

Screening for colorectal cancer: the accuracy of fecal occult blood.

Young GP, St John DJ.

JAMA. 1993 Jul 28;270(4):451-2; author reply 452-3. No abstract available.

PMID:
8320780
40.

Measurement of occult upper gastrointestinal tract blood loss: a direct comparison of radiochromium and haem-porphyrin assay techniques.

Young GP, St John DJ, Lynch NM, McHutchison JG, Barraclough D.

J Gastroenterol Hepatol. 1993 Jul-Aug;8(4):328-33.

PMID:
8374088
41.

Evaluation of new occult blood tests for detection of colorectal neoplasia.

St John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JC.

Gastroenterology. 1993 Jun;104(6):1661-8.

PMID:
8500724
42.

Cancer risk in relatives of patients with common colorectal cancer.

St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES.

Ann Intern Med. 1993 May 15;118(10):785-90.

PMID:
8470852
43.

Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia.

St John DJ, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA.

Ann Intern Med. 1992 Sep 1;117(5):376-82.

PMID:
1503328
44.

Readability and sensitivity of a new faecal occult blood test in a hospital ward environment. Comparison with an established test.

Petty MT, Deacon MC, Alexeyeff MA, St John DJ, Young GP.

Med J Aust. 1992 Mar 16;156(6):420-3.

PMID:
1545750
45.

Screening tests for colorectal neoplasia.

St John DJ.

J Gastroenterol Hepatol. 1991 Nov-Dec;6(6):538-44. No abstract available.

PMID:
1782366
46.

Clinical profile in Barrett's esophagus: who should be screened for cancer?

Collins BJ, Abbott M, Thomas RJ, Morstyn G, St John DJ.

Hepatogastroenterology. 1991 Aug;38(4):341-4.

PMID:
1937380
47.

Colorectal cancer.

St John DJ, Young GP.

Med J Aust. 1990 Nov 5;153(9):564. No abstract available.

PMID:
2233487
48.

Will colorectal cancer screening be too costly?

St John DJ.

Aust N Z J Surg. 1990 Jun;60(6):415-7. No abstract available.

PMID:
2346438
49.

Haem in the gut. Part II. Faecal excretion of haem and haem-derived porphyrins and their detection.

Young GP, St John DJ, Rose IS, Blake D.

J Gastroenterol Hepatol. 1990 Mar-Apr;5(2):194-203. Review.

PMID:
2103398
50.

Effect of ingestion of hemoproteins on fecal excretion of hemes and porphyrins.

Rose IS, Young GP, St John DJ, Deacon MC, Blake D, Henderson RW.

Clin Chem. 1989 Dec;35(12):2290-6.

Supplemental Content

Loading ...
Support Center